Introduction
Ets1, a member of the Ets family of transcription factors, is expressed by endothelial cells during the formation of new blood vessels. In vivo, Ets1 transcripts are expressed in endothelial precursors during vasculogenesis and in endothelial cells during angiogenesis in the embryo (Maroulakou et al., 1994; Pardanaud and Dieterlen-LieÁ vre, 1993; Queva et al., 1993; Vandenbunder et al., 1989) . Ets1 expression is not detected in quiescent endothelial cells in adult tissues (Wernert et al., 1992) , but it is induced in these cells during the formation of new blood vessels in solid tumors Wernert et al., 1992) , in the granulation tissue during wound-healing (Wernert et al., 1992) , and after denudation of the aortic endothelium (Tanaka et al., 1998) . In vitro, Ets1 is expressed by proliferating (Wernert et al., 1992) and migrating (Tanaka et al., 1998) endothelial cells but not after these cells have reached con¯uence (Wernert et al., 1992) . Expression is also increased by angiogenic factors such as tumor necrosis factor a, ®broblast growth factor-2 ( 1 FGF-2), transforming growth factor b and vascular endothelial growth factor/vascular permeability factor (VEGF) (Iwasaka et al., 1996; Wernert et al., 1992) . Ets1 expression is not restricted to the endothelium since its mRNA are also found in the somites and migrating neural crest cells in the embryo (Vandenbunder et al., 1989) , and in stromal ®broblasts of invasive tumors Wernert et al., 1994) . Nevertheless, the expression of Ets1 transcripts is associated with the activation of endothelial cells and the induction of angiogenesis, and these observations suggest that Ets1 plays a role in endothelial cells during the establishment of new blood vessels. Among Ets members, erg and¯i1 are coexpressed with ets1 in endothelial cells in the embryo (Vandenbunder et al., 1989; Dhordain et al., 1995; Macias et al., 1998; Mager et al., 1998) , suggesting that these factors could play a redundant role with Ets1 during angiogenesis.
Ets1 is a transcription factor that shares a similar DNA-binding domain with other members of the family. This binding domain recognizes the core sequence GGAA/T, named the Ets-binding site (EBS) (Gunther et al., 1990) . In vitro, Ets factors transactivate the promoters of several genes that are important in angiogenesis such as the genes encoding VEGF-R1 (Wakiya et al., 1996) , the platelet-derived growth factor-B chain (Khachigian et al., 1994) , the a4 integrin sub-unit (Rosen et al., 1994) and the receptor Tie (Iljin et al., 1999) . A few Ets1 target genes have been already identi®ed by analysis of endogenous transcripts in Ets1-over-expressing cells. Chicken Ets1 induces the expression of Ets1 (Seth and Papas, 1990) and Egr1 (Robinson et al., 1997) in mouse 3T3 stable transfectants. In mouse MSS-31 endothelial cells, murine Ets1 increases the mRNA levels of angiogenesis-related molecules such as MMP-1, -3, -9 and the b3 integrin sub-unit (Oda et al., 1999) . Identi®cation of Ets1 target genes in endothelial cells remains an important issue for understanding the role of this factor in angiogenesis.
VE-cadherin is a cell surface glycoprotein speci®-cally expressed by endothelial cells during mouse development and located at intercellular junctions in vivo and in vitro (Lampugnani et al., 1992; Breier et al., 1996) . VE-cadherin regulates the growth of transfected CHO cells and is essential for the integrity of the endothelial monolayer (Navarro et al., 1995) . VE-cadherin is also involved in the formation of capillary-like structures (Bach et al., 1998) and in the organization of endothelial cells into embryonic bodies in vitro (Vittet et al., 1997) . VEcadherin regulates cell response to VEGF and cell survival by interacting with VEGF-R2 at cell contacts (Carmeliet et al., 1999; Rahimi and Kazlauskas, 1999) . Inactivation of the VE-cadherin gene is lethal in mouse embryos and results in major defects in vascular development (Gory-FaureÂ et al., 1999; Carmeliet et al., 1999) . In particular, vasculogenesis in the yolk sac is severely impaired, due to the absence of blood island branching. The 72486/+24 region of the VE-cadherin gene promoter drives the speci®c expression of the gene in endothelial cells . Several EBS have been identi®ed in the 7139/+24 region; two are essential for transcriptional activity of the promoter in ®broblasts and endothelial cells (Gory et al., 1998) . The Etsfamily members that bind to the proximal promoter and the transcription factors that mediate endothelial speci®city have not been identi®ed so far.
We have over-expressed Ets1 in mouse brain capillary endothelial cell lines and 3T3 ®broblasts using a recombinant retrovirus. This over-expression decreased cell density at con¯uence of endothelials but not of ®broblasts. VE-cadherin expression was upregulated in response to Ets1 and repressed by a dominant negative mutant of Ets family members and by an Ets1 anti-sense oligonucleotide. Ets1 directly bound and activated the promoter region of the VEcadherin gene. Together with the comparison of their expression patterns in the embryo, our results suggest that Ets1 participates in the control of the VE-cadherin gene in vivo.
Results

Viral constructions and expression of Ets1 in infected cells
In order to generate cell lines that constitutively overexpressed a tagged Ets1 protein (TagEts1), the mouse Ets1 cDNA was cloned into the genome of a replication-de®cient MFG retrovirus (Drano et al., 1993) as shown in Figure 1 . The bicistronic construct was designed to allow separate expression of the TagEts1 protein and the neomycin resistance by the infected cells. GP+E86 packaging cells (Markowitz et al., 1988) were transfected with the pMFG-TagEts1 or the pMFG-Neo plasmid and selected with the neomycin analog geneticin. Mouse 3T3 ®broblasts, MBE and IBE endothelial cells were infected with the GP+E86 supernatant which contained either the control MFG-Neo or the MFG-TagEts1 retrovirus and selected for geneticin resistance until stable cell lines were established (approximately 10 days). Corresponding non-infected cells were treated in the same conditions, except for geneticin selection, and analysed in parallel to cell lines that were infected with the MFG-Neo virus (7Neo cells) or with the MFGTagEts1 virus (7Ets1 cells) throughout the study. RT-PCR analysis showed a marked increase in Ets1 mRNA levels in all 7Ets1 cell lines ( Figure 2A ) whereas basal levels of ets1 transcripts were not noticeably dierent in non-infected and 7Neo cell lines. Overall, except as mentioned in Figure 4 , no dierences were seen between non-infected and 7Neo control cells.
Over-expression of the TagEts1 protein in 7Ets1 cells was visualized by Western-blot using antibodies directed against the Tag epitope, or by using an antibody that detected both the endogenous and virusexpressed Ets1 ( Figure 2B ). Transcriptional activity on the EBS-driven reporter vector pTORU-tk-Luc was increased two to 2.4-fold in 3T3-Ets1 cells when compared to 3T3 and 3T3-Neo cells (Figure 3) , showing that the over-expressed TagEts1 was functional in the infected cells.
Taken together, the above data show that the retroviral system used eciently transferred the exogenous tagets1 gene to the target cells and that expression of this gene resulted in the production of an active TagEts1 protein.
Ets1 lowers density at confluence of endothelial cells
Right after infection and thereafter, we noticed an apparent lower growth rate of IBE-Ets1 and MBE-Ets1 when compared to control and 7Neo cells cultured under identical conditions. At con¯uence, all cells formed a continuous monolayer but the density of 7Ets1 cells appeared much lower than that of control and 7Neo cells (not shown). Proliferation curves showed that IBE-Ets1 and MBE-Ets1 reached a plateau of con¯uence at nearly half the density of both respective control cell lines (Figure 4 ). After 10 days of culture (more than 3 days after reaching con¯uence), the density of IBE-Ets1 monolayers reached 65% of IBE and IBE-Neo cell density and the density at con¯uence of MBE-Ets1 was 46% of MBE and 58% of MBE-Neo monolayers (Figure 4) . In contrast to brain capillary cells, 3T3-Ets1 grew at the same rate than control and 7Neo cells (Figure 4 ) and reached a similar density at con¯uence. Bisbenzimide staining and microscope observation did not reveal any increase in cell death that could explain the apparent lower rate of growth of MBE-Ets1 or IBE-Ets1 (not shown).
Ets1 induces the expression of endogenous VE-cadherin
Endothelial cell growth and density at con¯uence are regulated in part by the expression of N-and VEcadherin on the cell surface . There were no dierences in the expression of endogenous N-cadherin transcripts in 7Ets1 cells when compared to control cells ( Figure 5A ). On the other hand, there was a marked increase in the production of VE-cadherin mRNA in all 7Ets1 cells when compared to control cell lines ( Figure 5A ). This increase in the levels of VE-cadherin transcripts (C) H5V endothelial cells were transfected with the pMFG-Ets1-DB dominant negative mutant encoding plasmid (DB, (Mattot et al., 2000) or with pUC19 (mock) vector. Cell extracts (10 mg) were assayed for VE-cadherin (VE-cadh) or b-actin content by Western-blot. Equal eciency of transfection was checked by co-transfection with 3 mg of pCMV-GFP vector and¯uorescence observation. 7, non-transfected cells. (D) H5V cells were treated with medium (7), transfection reagent (mock), an Ets1 antisense (anti-sense) or sense (sense) oligonucleotide and cell extracts were prepared and analysed as in C Ets1 transcription factor activates the VE-cadherin gene E Lelie Á vre et al correlated with an accumulation of the protein in all 7Ets1 cells as evidenced by Western blot analysis ( Figure 5B ). Although IBE-Ets1 showed an increase in VE-cadherin transcripts similar to that seen in MBEEts1, protein expression was rather limited in these cells. In order to test whether the expression of endogenous VE-cadherin was controlled by Ets1 in noninfected cells, we ®rst transfected H5V endothelial cells with a plasmid encoding the DNA-binding domain of Ets1, which acts as a dominant negative mutant of Ets factors (Mattot et al., 2000) . The mutant induced a marked decrease in VE-cadherin protein expression as compared to non-and mock-transfected cells ( Figure  5C ). Second, we transfected H5V cells with oligonucleotides corresponding to the region of the Ets1 start codon, either in sense or anti-sense orientation. The anti-sense nucleotide reduced endogenous VE-cadherin expression in H5V cells whereas the sense oligonucleotide had no eect ( Figure 5D ), thus con®rming that VE-cadherin expression was under the control of Ets1 in these cells.
Immuno¯uorescence analysis revealed a typical localization of VE-cadherin at cell contacts in 7Ets1 cells ( Figure 6 ). VE-cadherin expression was fainter in IBE-Ets1 cells as already found in Western blot analysis. The cell contacts were decorated with the antibody mainly as dotted lines instead of the strong zipper-like staining seen in MBE-Ets1 and 3T3-Ets1 cells. A zipper-like staining could sometimes be observed with IBE-Ets1 cells. No detectable expression of VE-cadherin at intercellular contacts was seen in control MBE, IBE and 3T3, and 7Neo cells grown at con¯uence (Figure 6 ).
Activation of the VE-cadherin promoter by Ets1
Several EBS are present in the promoter of the VEcadherin gene (Huber et al., 1996; Gory et al., 1998) . In order to analyse the putative role of Ets1 in the control of this promoter, we performed transactivation experiments using an Ets1-expression plasmid and the 72486CAT VE-cadherin gene reporter vector, which contains the 72486/+24 promoter sequence of VEcadherin placed upstream a chloramphenicol acetyl transferase gene . This promoter sequence contains most if not all the sequences involved in the control of the VE-cadherin gene in vivo since it directs reporter expression in transgenic mice speci®cally in endothelial cells where the endogenous VE-cadherin gene is expressed . Transient transfection of the pMFGTagEts1 vector in 3T3 cells induced a 4.4+0.2-fold activation of the 72486CAT reporter vector over pBLCAT3 control. In order to identify the EBS present in this region that are involved in the regulation of the protein gene by Ets1, we produced a recombinant Ets1 (rEts1) and analysed its binding to ®ve EBS among which two (EBS2 and EBS4) are known to be necessary for gene expression (Gory et al., 1998) . rEts1 bound to EBS2 and to EBS4 and to the control MSV-LTR EBS ( Figure 7A ) but not to EBS1, EBS3 or EBS5. Binding seemed more eective on EBS4 than on EBS2, and in all cases, it was supershifted in the presence of an anti-Ets1 antibody. Binding of rEts1 to EBS2 and EBS4 was speci®c since it was competed for in the presence of a 100-fold excess of unlabelled probe and not in the presence of unlabelled probe in which the EBS sequence had been Figure 6 Immuno¯uorescence staining of VE-cadherin. MBE, 3T3 and IBE monolayers were stained using an anti-VE-cadherin antibody. VE-cadherin concentrated at cell-cell contacts in MBE-Ets1 and 3T3-Ets1 cells (arrowheads) whereas over-expression was seen throughout the cell in IBE-Ets1 cells. There was no VE-cadherin expression at free cell-edges (arrows) and VE-cadherin was not detected in non-infected or 7Neo cells in all cases. Data are representative of at least two independent experiments performed in similar conditions with each cell line. Bar represents 10 mm mutated ( Figure 7B ). As expected, rEts1 did not bind to the mutated version of the EBS2 or EBS4 ( Figure  7B) .
We then performed co-transfection experiments using the same 72486/+24 promoter sequence as above placed upstream of a luciferase reporter gene. Transient transfection of pMFG-TagEts1 induced a 2.80+0.04-fold activation of the 72486LUC reporter vector. Mutation of EBS2 decreased the levels of transactivation to 1.71-fold+0.10 over control whereas mutation of EBS4 almost abolished transactivation (1.27-fold+0.02 of control levels) (Figure 8 ). Mutation of both EBS2 and EBS4 completely abolished the transactivating activity of Ets1 on the VE-cadherin promoter (0.88+0.06-fold of control, Figure 8) , showing that most of Ets1 activity on the VE-cadherin promoter was mediated through these two EBS.
Together, all these data show that Ets1 is involved in the control of the expression of the endogenous VEcadherin gene through activation of EBS2 and EBS4 and that both EBS are necessary for transactivation of the gene by Ets1.
Discussion
In the present study, we have used a MFG retroviral vector in order to over-express Ets1 in brain capillary endothelial cells and ®broblasts. This approach was chosen primarily because endothelial cells are notoriously refractory to transfection and our experiments validated this choice: the MFG retrovirus transduced the gene to the cells with more than 80% eciency and the viral promoter provided signi®cantly higher expression levels of Ets1 transcripts and proteins in Figure 7 Binding of Ets1 to functional EBS in the VE-cadherin gene. (A) Recombinant Ets1 (rEts1, approximately 1 ng) was assayed for binding to 32 P-labeled double-stranded oligonucleotides (10 ng) corresponding to the various EBS present in the proximal region of the VE-cadherin gene (Gory et al., 1998) by electromobility-shift assay. The complexes formed by rEts1 and EBS2 or EBS4 were super-shifted by the addition of 250 ng of anti-Ets1 antibody (SS). free: free probe. Only the upper part of the gel is presented. (B) Binding of rEts1 to 32 P-labeled EBS2 and EBS4 (10 ng) was prevented by the addition of a 100-fold excess of unlabeled probe (6100 wt) but not by addition of a 100-fold excess of the mutated probe (6100 mut). The complexes were super-shifted in the presence of 250 ng of anti-Ets1 antibody (SS) whereas the antibody had no eect on the migration of the probe alone (Ab). rEts1 did not bind to the 32 P-labeled mutated probes MSV-LTRmut, EBS2mut or EBS4mut. free: free probe. The upper parts of the EBS2 and EBS4 gels are presented. Data are representative of at least three independent experiments performed in similar conditions 7Ets1 cells compared to controls. Infection with the control MFG-Neo virus had no detectable eects on the cells aside from a slight inhibition of the density at con¯uence of MBE-Neo. After infection, the ®rst obvious eect of Ets1 expression was a reduction by nearly half of cell density at con¯uence of both MBE-Ets1 and IBE-Ets1 endothelial cells, with no apparent increase in cell death. This was unexpected since previous studies on the eects of Ets1 over-expression on cell proliferation in vitro had yielded contradictory results, probably due to dierences in species origin between Ets1 and the cells used (Seth and Papas, 1990; Suzuki et al., 1995) but none had reported an eect on cell density at con¯uence. The sole report describing the overexpression of mouse Ets1 in endothelial cells derived from mouse spleen showed no dierences in cell growth or apoptosis, nor in the morphology of the cells (Oda et al., 1999) . This, added to our results, suggests that the decrease in cell density at con¯uence induced by mouse Ets1 could be restricted to brain capillary endothelial cells. This hypothesis is however still to be con®rmed.
N-and VE-cadherin are known to regulate endothelial cell density at con¯uence and we reasoned that cadherin expression could be regulated by Ets1. Indeed, VE-cadherin transcripts levels were increased in all 7Ets1 cells whereas Ncadherin levels were not aected. At the protein level, over-expression was variable depending on the cells. Although VE-cadherin transcripts levels were similar in IBE-Ets1 and MBE-Ets1, IBE-Ets1 accumulated less protein than MBE-Ets1, either as a result of a lower translation of the VE-cadherin transcripts or of a lower stability of the protein once it was expressed in these cells. Immuno-¯uorescence experiments also revealed that VE-cadherin distribution was dierent in IBE-Ets1, with a rather faint accumulation at cell contacts. These dierences in expression and localization between various cell types raise interesting points: it is probable that the increase in VE-cadherin expression is responsible only in part for lowering cell density at con¯uence since IBE-Ets1 showed limited expression of VE-cadherin at cell-contacts and still a marked decrease of density at con¯uence. This could mean that VE-cadherin does not need to be present at high levels, or maybe even at all, at cellcontacts in order to mediate the decrease in cell density. Indeed, the eects of VE-cadherin on cell growth are dependent on its association with b-catenin and VE-cadherin reportedly remains associated with catenins when endothelial cells are treated with an antibody that disrupts VEcadherin localization from cell contacts (Corada et al., 1999) . This supports the idea that the growth inhibition pathway activated by the binding of bcatenin to VE-cadherin still functions when the cadherin is not localized at cell-contacts. Finally, VE-cadherin is not sucient either to mediate a cell density decrease since 3T3-Ets1 cell density at con¯uence is not aected by high levels of the protein and by its presence at cell contacts. In 3T3, b-catenin does interact with VE-cadherin (not shown), suggesting that the pathway mediating a decrease of cell density at con¯uence could be blocked downstream of the VE-cadherin/catenins complexes in these cells. As seen above, it is also possible that Ets1 regulates the transcription of other genes that, together with VEcadherin, aect density at con¯uence speci®cally in endothelial cells.
Whether VE-cadherin is a direct or indirect target gene of Ets1 is dicult to assess. The use of dominant negative mutant of Ets members and of Ets1 antisense oligonucleotides showed that VE-cadherin was expressed under the dependence of the endogenous Ets1 factor produced in H5V cells. EMSA experiments also showed that Ets1 was able to directly bind to EBS2 and EBS4 in the VE-cadherin promoter, supporting the hypothesis of a direct control of the gene by Ets1. We still cannot rule out the possibility that Ets1 may activate this promoter through or together with another, yet unidenti®ed, transcription factor since, in addition to its own promoter (Oka et al., 1991) , Ets1 is known to regulate the jun-B (Coer et al., 1994) and GATA-1 (Seth et al., 1993) promoters. No functional binding sites for these factors have been seen in the VE-cadherin promoter (unpublished results).
The VE-cadherin promoter region used here contains most if not all of the necessary information for VEcadherin gene control in the embryo . Since the double EBS2/EBS4 mutant did not respond to Ets1 anymore, there must be no additional Ets1-responding sites left in the rest of the promoter. A previous study using a shorter version of the promoter had shown that EBS2 and EBS4 were necessary to the basal transcriptional activity of the promoter in endothelial cells, and that EBS4 was more eective than EBS2 for this activity (Gory et al., 1998) . Here, we suggest that Ets1 could be the Ets member that mediates these eects: (i) EBS2 and EBS4 are necessary for transactivation by Ets1, (ii) transactivating activities of EBS2 and EBS4 are additive in response to Ets1, (ii) EBS4 is more responsive to Ets1 than EBS2, this latter eect being probably due to its better binding to rEts1 than EBS2 (Figure 7a) .
Regarding Ets1 speci®city of binding to DNA, our EMSA results are in accordance with what was already known on the structure of the Ets1 binding site (Fisher et al., 1991; Ghysdael and Boureux, 1997; Woods et al., 1992) . rEts1 bound to EBS2 and EBS4 but failed to bind to EBS1, EBS3 or EBS5, although they had the correct GGAA/T core sequence. These results support the previous observations that an A in position 73 relative to the ®rst G of the core sequence and a G in position +5 favor binding of Ets1 to DNA (Fisher et al., 1991; Nye et al., 1992; Woods et al., 1992) .
Could Ets1 be involved in the regulation of VEcadherin expression in vivo? In situ hybridization studies of ets1 and VE-cadherin expression in the mouse embryo showed a strong correlation between the expression of both genes in the endothelial lineage (Breier et al., 1996; Grevin et al., 1993; Maroulakou et al., 1994; Vandenbunder et al., 1989) . Ets1 and VEcadherin are both expressed in the yolk sac mesoderm at the time of blood islands formation around E7.5. When blood islands mature, this expression becomes restricted to their periphery where endothelial cell precursors dierentiate. Expression of VE-cadherin and ets1 is also seen at these stages in the blood vessels of the maternal decidua. Around E9.5 to E11 and during organogenesis, expression of both genes is detected in the endothelium lining blood vessels of all developing organs investigated. These striking homologies in expression patterns support the idea that Ets1 takes part in the regulation of VE-cadherin expression in the embryo. On the other hand, ets1 is also expressed in tissues that do not express VE-cadherin such as the mesenchyme adjacent to epithelial structures during organogenesis (Breier et al., 1996; Grevin et al., 1993; Maroulakou et al., 1994) . In vitro, VE-cadherin transcripts are expressed by 3T3 ®broblasts when Ets1 is over-expressed, but ®broblastic cells in the mesenchyme do not express VE-cadherin during embryonic development (Breier et al., 1996) . This suggests that, in addition to Ets1, a control mechanism must exist in non-endothelial cells that represses VEcadherin expression in the presence of Ets1 in vivo. Such control would be lost or overruled by Ets1 overexpression in 3T3 cells in vitro. These observations suggest that Ets1 is able to turn the VE-cadherin gene on and suggests that other factors are necessary to restrict gene expression to vascular structures.
What could be the role of Ets1 in endothelial cells? Ets1 expression is induced in endothelial cells during angiogenesis in the embryo (Maroulakou et al., 1994; Pardanaud and Dieterlen-LieÁ vre, 1993; Queva et al., 1993; Vandenbunder et al., 1989 ) and its expression is lowered when endothelial cells reach con¯uence in vitro (Wernert et al., 1992) . This suggests that Ets1 plays a role in endothelial cell proliferation but this role is still undocumented. Angiogenesis involves the sprouting of a new blood vessel by cell proliferation and migration from the pre-existing quiescent endothelium. This requires a tight growth control and a balance between endothelial proliferation, to achieve the growth of the new vessel, and cell arrest, to dierentiate a capillary. Since Ets1 expression in endothelial cells derived from adult tissues leads to a lower cell density at con¯uence, we speculate that Ets1 expression in vivo may be induced in order to regulate endothelial cell proliferation during angiogenesis rather than to promote it, and to induce the cells to return to quiescence. Ets1 may in addition be involved in tube and lumen formation in sprouting blood vessels by inducing VE-cadherin expression, which is necessary for capillary formation in vitro (Bach et al., 1998; Vittet et al., 1997) and for the maintenance of the endothelium integrity in vivo (Navarro et al., 1995) .
Materials and methods
Material
Mouse brain capillary (MBE) endothelial cells (Auerbach, 1991) were a generous gift of Dr Robert Auerbach (University of Madison, Madison, USA) and Dr Marco Presta (University of Brescia, Brescia, Italy). Brain capillary endothelial cells (IBE) isolated from transgenic new born mouse (Kanda et al., 1996) were a generous gift of Dr Laena Claesson-Welsh (Ludwig Institute for Cancer Research, Uppsala, Sweden), and GP+E86 cells (Markowitz et al., 1988) of Dr Arthur Bank (Columbia University, New York, USA)). The pMFG plasmid (Drano et al., 1993) was kindly provided by Dr Richard Mulligan (Massachusetts Institute of Technology, Cambridge, USA). RT ± PCR reagents were from Perkin-Elmer. Oligonucleotides were from Genset, France.
Plasmid constructions
The coding sequence of the hemaglutinin in¯uenza virus epitope SYPYDVPDYASLGPG was cloned in frame with the murine Ets1 cDNA followed by an internal ribosome entry site and a neomycin resistance gene (pCITE, Novagen). This construction was inserted into the MFG retrovirus plasmid (Drano et al., 1993) using the Ncol-BamHl sites (pMFG-TagEts1, Figure 1) . A similar construction lacking the TagEts1 sequence was made and used throughout the study as a control (pMFG-Neo).
The VE-cadherin luciferase reporter vector 72486LUC was prepared by cloning the HincII/XhoI fragment of the 72486CAT vector (Gory et al., 1998) into the Ecl136ll/XhoI sites of the pGL3 basic plasmid (Promega). Mutated versions of the vector were made by exchanging the PstI/XhoI fragments of the 72486LUC vector by those of the 7139EBS2M, 7139EBS4M and 7139EBS24M CAT vectors (Gory et al., 1998) .
Cell culture, proliferation assay Mouse brain capillary (MBE) endothelial cells (Auerbach, 1991) , brain capillary endothelial cells isolated from transgenic new born mouse (IBE, Kanda et al., 1996) , H5V endothelioma cells, 3T3 ®broblasts and GP+E86 virusencapsidating cells (Markowitz et al., 1988) were cultured in DMEM containing 4.5 g/l glucose, 10% heat-inactivated calf serum (Hyclone), 8 mg/ml gentamycin, 50 U/ml penicillin, 50 mg/ml streptomycin. Na pyruvate (1 mM) was added to the MBE culture medium. Additional 10% serum, 2 ng/ml FGF-2 (R&D systems), 20 U/ml mouse g-interferon (R&D systems) were added to the IBE culture medium. Cells were cultured at 378C or 338C (IBE) in a 5% CO 2 /95% air humidi®ed atmosphere. For proliferation assays, cells were seeded onto 4 cm 2 wells at 3500, 7500 and 10 000 cells/cm 2 for IBE, MBE and 3T3, respectively, and cultured for the indicated amount of time. The medium was changed every other day and the cell number counted every day using a Coulter counter (Coultronics).
Viral production and infection
GP+E86 cells (150 000/10 cm 2 ) were transfected with the MFG plasmid constructs (2 mg) using lipofectamine (Life Technologies) and selected for geneticin resistance. 3T3, MBE, and IBE cells were infected with the GP+E86-produced MFG-Neo or MFG-TagEts1 viruses (=42.10 6 c.f.u./ml, not shown) essentially as described (Mattot et al., 2000) . Non-infected parent cells were maintained in culture and assayed at the same time and passage number than the 7Neo and 7Ets1 daughter cell lines throughout the study.
RT-PCR analysis
Total RNA were extracted from sub-con¯uent cells using the TRIzol reagent (Life Technologies). Reverse transcription reactions using 1 mg of RNA and random hexamer oligonucleotides (Perkin Elmer) were performed following the manufacturer's instructions. For PCR analysis, reverse transcription products were incubated in PCR buer II containing 1 mM of each speci®c primer (Genset, Table 1), 150 mM of each dNTP and 1.25 U AmpliTaq Gold in a ®nal volume of 50 ml. Reactions were heated for 5 min at 958C and several cycles of 1 min at 948C, 1 min at annealing temperature and 1 min at 728C were performed using a GeneAmp PCR System 9600 thermocycler (Perkin Elmer) as indicated in Table 1 . Products were analysed by electrophoresis in 1.2% agarose gels and visualized under UV illumination after ethidium bromide staining. In order to avoid the ampli®cation of genomic DNA, PCR primers were chosen so that the ampli®cation Ets1 transcription factor activates the VE-cadherin gene E Lelie Á vre et al product covered several exons of the gene of interest. Puri®cation and direct sequencing of PCR products con®rmed the identity of the ampli®ed products.
Western-blot analysis
Cell extracts (10 ± 60 mg) were analysed in SDS ± PAGE under reducing conditions (Laemmli, 1970) , transferred overnight at 48C onto a PVDF membrane (Immobilon P, Millipore) and proteins detected using antibodies directed against mouse VE-cadherin (Pharmingen), human Ets1 which recognized the mouse protein (Transduction Labs), Tag epitope (Babco) or b-actin (Santa Cruz) with the Aurora Western-blotting system (ICN).
Transfection and transactivation assays
H5V heart endothelial cells (750 000 cells/78.5 cm 2 dishes, (Garlanda et al., 1994) were transfected with 30 mg of pMFG-Ets1-DB (Mattot et al., 2000) or pUC19 plasmid, and with 3 mg of pCMV-GFP control plasmid, using Exgen 500 (Euromedex). For antisense experiments, cells were transfected with the GCCGCCTTCATGGTGCCCG Ets1-antisense or the CGGGCACCATGAAGGCGGC Ets1-sense phosphorothioate oligonucleotides (1 mM). Cell extracts were prepared 3 days later and analysed by Western-blot.
3T3, 3T3-Neo and 3T3-Ets1 cells (100 000 cells/10 cm 2 ) were transfected with increasing amounts of the optimized EBSreporter plasmid p-TORU-tk-Luc, composed of three closely positioned EBS-AP1 sites upstream of a minimal thymidine kinase promoter and the luciferase gene, and 250 ng of pCH110 standardization plasmid (Amersham Pharmacia) using lipofectamine (Life Technologies). For studies of the VE-cadherin promoter, 3T3 cells were transfected with pMFG-TagEts1 plasmid (0.014 pmoles), and with the indicated VE-cadherin gene reporter vectors (0.08 pmoles) and pCH110 standardization vector (0.054 pmoles, Pharmacia) using Exgen 500. Luciferase and b-galactosidase activities were measured in cell extracts using a Lumat luminometer LB9501 (Berthold). Chloramphenicol acetyl transferase activities were measured as described (Gorman et al., 1982) .
Electromobility-shift assays (EMSA)
Double-stranded oligonucleotide probes corresponding to the MSV-LTR (Gunther et al., 1990) , and the various VEcadherin EBS sites (Gory et al., 1998) were end-labeled using T 4 polynucleotide kinase and [ 32 P] g ATP and puri®ed on Biospin-30 columns (Biorad). Radiolabeled probes were mixed in HEPES 10 mM, pH 7.9, KCl 30 mM, EDTA 0.25 mM, EGTA 63 mM, DTT 1 mM, glycerol 10% (w:v), poly [dI-dC] .poly[dI-dC] (Pharmacia), recombinant Ets1 (approx. 1 ng), 1 mg non-labeled double-stranded oligonucleotide, 250 ng speci®c anti-Ets1 antibody (Transduction laboratories) where indicated. Samples were incubated for 10 min at room temperature and the products analysed by electrophoresis on a 6% acrylamide-bis gel in Tris 22.3 mM, boric acid 22.3 mM, 0.5 mM EDTA at 150 V. Gels were dried and autoradiographed.
Immunofluorescence staining
Cells grown to con¯uence onto gelatin-(MBE and 3T3) or MBE matrix-coated (IBE) 14 mm é glass coverslips were ®xed and permeabilized in PBS, 2% paraformaldehyde, 0.1% Triton6100 for 3 min at room temperature, post-®xed in PBS, 2% paraformaldehyde for 10 min, incubated in TrisHCl 10 mM, pH 8.0, NaCl 50 mM containing 10% goat serum (Life Technologies) for 1 h at room temperature, then in the presence of anti-VE-cadherin antibody (1/100, Pharmingen) for 1 h. Cells were rinsed and incubated in the presence of Cy3-labeled anti-rat antibody (1/500, Jackson Immunoresearch) for 1 h at room temperature, rinsed and mounted in Prolong Antifade medium (Molecular Probes). Immuno¯uorescence was examined using a Zeiss Axioplan 2 microscope and recorded with a video capture equipment (Princeton Instruments Inc.) . No signal could be detected if the primary antibody was omitted (not shown).
Abbreviations 3T3, mouse ®broblasts; EBS, Ets-binding site; H5V, mouse heart endothelioma cells; IBE, new born mouse brain capillary endothelial cells, MBE mouse brain capillary endothelial cells; EMSA, electromobility-shift assay; rEts1, recombinant Ets1; Tag, haemophilus in¯uenzae hemaglutinin epitope; FGF-2, ®broblast growth factor-2; VEGF, vascular-endothelial growth factor/vascular permeability factor.
